سعر اربيفيوتال كو 150/12.5 مجم 30 قرص 2025

Irbefutal co 150/12.5 mg 30 tab: tablets containing irbesartan 150 mg + hydrochlorothiazide 12.5 mg (Future Pharmaceutical Industries (FPI)).

• Treatment of hypertension; may be used when blood pressure is not adequately controlled on monotherapy, or as initial therapy in patients likely to need multiple drugs.Population: Adults with hypertensionDailyMed (U.S. National Library of Medicine)

• In trials, adverse events were limited to those previously reported with irbesartan or hydrochlorothiazide; no events peculiar to the combination were observed.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to any component; anuria; hypersensitivity to other sulfonamide-derived drugs (HCTZ component).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Do not coadminister aliskiren in patients with diabetes.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning - fetal toxicity: discontinue as soon as pregnancy is detected; RAS-acting drugs can injure and kill the developing fetus.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Symptomatic hypotension in volume- or sodium-depleted patients; correct depletion before starting.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Electrolyte and metabolic imbalances (hypokalaemia 7.5% vs 6.0% placebo in trials); renal function changes in susceptible patients.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• NSAIDs including COX-2 inhibitorsMay worsen renal function and attenuate the antihypertensive effect; monitor renal function.DailyMed (U.S. National Library of Medicine)
• Dual RAS blockade / aliskirenAvoid combined RAS inhibitors; do not use aliskiren in diabetes; avoid aliskiren if GFR <60 mL/min.DailyMed (U.S. National Library of Medicine)
• Agents increasing serum potassiumRisk of hyperkalaemia; monitor potassium.DailyMed (U.S. National Library of Medicine)

• Can cause fetal harm: RAS-acting drugs in the 2nd/3rd trimesters reduce fetal renal function and increase fetal/neonatal morbidity and death; thiazides cross the placenta (risk of fetal/neonatal jaundice, thrombocytopenia). Discontinue when pregnancy is detected.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Irbesartan is secreted in rat milk and thiazides appear in human milk; breastfeeding is not recommended.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Irbesartan: Selectively blocks the binding of angiotensin II to the AT1 receptor, inhibiting its vasoconstrictor and aldosterone-secreting effects.
• Hydrochlorothiazide: Promotes renal excretion of sodium and chloride, reducing intravascular volume.